Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

CaDAnCe-302, a phase 3, open-label, randomized study of BGB-16673 compared with idelalisib + rituximab (R), bendamustine + R, or venetoclax + R re-treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma previously exposed to both a BTK and BCL2 inhibitor

Constantine Tam, John Seymour, Jiayi Shen et al. Nov 03, 2025 pp. 8245-8245 10.1182/blood-2025-8245

Abstract Introduction: Novel therapies, including Bruton tyrosine kinase (BTK) inhibitors and B-cell lymphoma 2 (BCL2) inhibitors, have mean...

No overall increased risk of death or cardiovascular disease in individuals with sickle cell trait: A prospective study of 467,957 general population adults

Marie Warny, Jens Helby, Shoaib Afzal et al. Nov 03, 2025 pp. 4440-4440 10.1182/blood-2025-4440

Abstract Introduction Sickle cell trait (SCT) is among the most prevalent carrier states on earth. While traditionally considered benign, un...

Causes of death in chronic lymphocytic leukemia/small lymphocytic lymphoma during the novel agent era: A population-based analysis

Mengyang Di, Scott Huntington, Jenna Voutsinas et al. Nov 03, 2025 pp. 4520-4520 10.1182/blood-2025-4520

Abstract Background: Chemoimmunotherapy (CIT) had long been used to treat chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)...

County-level analysis reveals two high-incidence regions and potential environmental contributors to myeloid malignancies in Colorado

Jason Gilbert, Diana Abbott, Elizabeth Molina Kuna et al. Nov 03, 2025 pp. 2853-2853 10.1182/blood-2025-2853

Abstract Background: Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are hematologic malignancies that result from an accumu...

Metabolic signatures mirror divergent modalities of leukemia immune evasion and relapse after transplantation

Annalisa Tameni, Emanuele Rondelli, Angela Gentile et al. Nov 03, 2025 pp. 590-590 10.1182/blood-2025-590

Abstract Acute myeloid leukemia (AML) relapse after allogeneic hematopoietic cell transplantation (allo-HCT) is increasingly recognized as a...

A first-in-human study of CT0596, an allogeneic CAR T-cell therapy targeting BCMA, in patients with relapsed/refractory multiple myeloma

Juan Du, Lina Jin, Wanting Qiang et al. Nov 03, 2025 pp. 2296-2296 10.1182/blood-2025-2296

Abstract Introduction Universal CAR T-cell therapy addresses key challenges of autologous CAR T, including high cost, time-consuming, person...

Journey of relapsed or refractory multiple myeloma (RRMM) after quadruple-class exposure (QCEx): Poor outcomes and high attrition

Doris Hansen, Lin Wang, Fangyi Gu et al. Nov 03, 2025 pp. 5771-5771 10.1182/blood-2025-5771

Abstract Introduction: Patients with RRMM who have been exposed to 4 classes of treatment (quadruple-class exposed; QCEx) with proteasome in...

Mapping proteomic signatures in iPSC-derived neutrophils: Modeling neutropenia

Megha Mukherjee, Alicia-Sophie Schebesta, Daniel Petersheim et al. Nov 03, 2025 pp. 1212-1212 10.1182/blood-2025-1212

Abstract Severe congenital neutropenia (SCN) encompasses a diverse range of genetic defects that impair the differentiation and function of...

Safety characteristics of brentuximab vedotin among patient subgroups: Insightsfrom pooled clinical trial database

Heather Ward, Wamiq Zaidi, Paul Cernohous et al. Nov 03, 2025 pp. 1925-1925 10.1182/blood-2025-1925

Abstract Rationale and background: For the approval of new drug products or label expansions, conducting clinical trials that are fully repr...

Prevalence, clinical implications and impact of stem cell transplantation in UBTF-TD positive AML

Valeria Ceolin, Rhonda Ries, Jack H. Peplinski et al. Nov 03, 2025 pp. 221-221 10.1182/blood-2025-221

Abstract Background: Recurrent tandem duplications (TDs) of upstream binding transcription factor (UBTF) have recently been described in adu...

Germline alterations of hematopoietic growth factor receptors and maladaptive somatic genetic rescue leads to myeloid neoplasia

Serhan Unlu, Tariq Kewan, Christopher Haddad et al. Nov 03, 2025 pp. 5614-5614 10.1182/blood-2025-5614

Abstract Using rationally targeted NGS screen, we have previously identified germ line (GL) alteration in genes linked to hereditary bone ma...

Characteristics and outcomes for patients with concomitant myeloproliferative neoplasms (MPN) and autoimmune disorders

Hannah Goulart, Grace Park, Prithviraj Bose et al. Nov 03, 2025 pp. 2037-2037 10.1182/blood-2025-2037

Abstract Introduction Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders characterized by dysregulated prolife...

Targeting hedgehog signaling/KL4-dependent M2 macrophage polarization for treatment of chronic graft-versus-host diseases and tissue fibrosis

Chunhua Song, Benjamin Kaffenberger, Chelsea Steiner et al. Nov 03, 2025 pp. 583-583 10.1182/blood-2025-583

Abstract Background: Chronic graft-versus-host disease (cGVHD) represents the leading cause of non-relapse-related mortality and morbidity f...

Evaluation of cytarabine consolidation dosing in older adult patients with Acute Myeloid Leukemia

Pooja Kumar, Deedra Nicolet, Tracelyn Freeman et al. Nov 03, 2025 pp. 3408-3408 10.1182/blood-2025-3408

Abstract Introduction: Post remission therapy in patients (pts) with acute myeloid leukemia (AML) who are intensive indu...

National alliance of sickle cell centers consensus recommendations for defining an adult sickle cell disease specialist

Francis Coyne, Sheinei Alan, Mohan Madisetti et al. Nov 03, 2025 pp. 6419-6419 10.1182/blood-2025-6419

Abstract Background Sickle cell disease (SCD) affects at least 100,000 people in the United States (US). Acute pain is the most common reaso...

Diagnostic relevance of SH2B3 mutations in suspected myeloid malignancies: Insights from a large-scale NGS-based screening study

Leïla BEN DHIA, Mathieu Wemeau, Laurene Fenwarth et al. Nov 03, 2025 pp. 2016-2016 10.1182/blood-2025-2016

Abstract INTRODUCTION The SH2B3 gene encodes the cytoplasmic adaptor protein LNK that acts as a negative regulator of hematopoietic progenit...

Novel small molecule inhibitors of mitochondrial permeability transition pore (mPTP) block platelet procoagulant activity

Yiheng Zhang, Jordan Sandler, Osamede Owegie et al. Nov 03, 2025 pp. 2549-2549 10.1182/blood-2025-2549

Abstract Subpopulations of procoagulant platelets expose phosphatidylserine (PS) on their plasma membrane, providing a catalytic surface for...

Convergence in age adjusted mortality rates and proportion of all deaths from COVID-19 among patients with hematologic malignancies, 2020-2024

James Di Palma-Grisi, Evan Locke, Andrew Ip Nov 03, 2025 pp. 8150-8150 10.1182/blood-2025-8150

Abstract Introduction: Patients with hematologic malignancies (HM) are often immunocompromised, either as a result of their illness or its t...

Comparative evaluation of ipss-m and cpss-mol in CMML: Impact of molecular markers on prognosis

Alexander Streuer, Yotaro Ochi, Yasuhito Nannya et al. Nov 03, 2025 pp. 3860-3860 10.1182/blood-2025-3860

Abstract Introduction Chronic myelomonocytic leukemia (CMML) is a heterogeneous hematologic malignancy with overlapping...

The B2M–LILRB1 axis as a novel myeloid immune checkpoint and therapeutic target in multiple myeloma

Marcello Turi, Pietro Folino, Francesca Barello et al. Nov 03, 2025 pp. 1032-1032 10.1182/blood-2025-1032

Abstract Cancer immunotherapies have shown significant promise in multiple myeloma (MM). However, their long-term efficacy is limited by imm...

Double jeopardy: Heart failure and thrombotic thrombocytopenic purpura in the inpatient setting

Abdulmalek Aljafari, Mohamed Elganainy, Roshni Soni et al. Nov 03, 2025 pp. 2696-2696 10.1182/blood-2025-2696

Abstract Background: Thrombotic thrombocytopenic purpura (TTP) is a life-threatening microangiopathic disorder requiring urgent intervention...

Comparative effectiveness of emergency department versus pain infusion clinic management for acute pain in adults with sickle cell disease: Implications for cost and timeliness of care

Daniel Sop, Yue Zhang, Shirley Johnson et al. Nov 03, 2025 pp. 122-122 10.1182/blood-2025-122

Abstract Background: Acute pain is the most common reason for healthcare utilization among adults living with Sickle Cell Disease (SCD). Whi...

Impact of VEGF inhibition on the development of erythrocytosis in hereditary hemorrhagic telangiectasia

Zureyat Sola-Odeseye, Malcolm Su, Ibrahim Ibrahim Nov 03, 2025 pp. 3083-3083 10.1182/blood-2025-3083

Abstract Introduction In hereditary hemorrhagic telangiectasia (HHT), erythrocytosis is typically attributed to chronic...

Real-world factor VIII trough levels of severe-type people with Hemophilia A (PwHA) on efanesoctocog alfa prophylaxis: Interpersonal variation, clinical correlates and predictors

Chia-Yau Chang, Tefu Weng, Shiue-Wei LAI et al. Nov 03, 2025 pp. 3063-3063 10.1182/blood-2025-3063

Abstract Introduction: Efanesoctocog alfa (EA) is a high-sustained FVIII, designed to decouple FVIII from endogenous von Willebrand factor (...

Exploring the relationship between serum iron, patient morbidity, mortality, and length of hospitalization in a burn center

Taha Hassan, Zheyar Seyan, Merry Matthew et al. Nov 03, 2025 pp. 7907-7907 10.1182/blood-2025-7907

Abstract Iron is ubiquitous within the human body and serves numerous functions. Given its roles in oxygen transport, immune function, and w...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page